Anzeige
Erschienen in:
01.12.2007
CA 19-9 and Survival in Advanced and Unresectable Pancreatic Adenocarcinoma and Cholangiocarcinoma
Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2-4/2007
Einloggen, um Zugang zu erhaltenAbstract
Background
The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear.
Aim of study
To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study.
Methods
A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma.
Results
Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of ≥20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2–23.5) compared to 7.6+ months (range 4.0–14.7) in those without such a change (p = 0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0–41.4) vs 6.2 months (range 3.1–9.4; p = 0.0075).
Conclusions
The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice.